News

23 02, 2023

Join Avance Biosciences™ at BioProcess International West – Feb 27-Mar 2, 2023!

2023-02-23T15:24:12+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Join Avance Biosciences™ at BioProcess International West – Feb 27-Mar 2, 2023!2023-02-23T15:24:12+00:00
21 02, 2023

Weill Cornell study demonstrates safety of intravenous administration of an AAV8 gene therapy

2024-07-13T13:31:10+00:00

Researchers report on the safety of a gene therapy to treat the common autosomal recessive hereditary disorder alpha 1-antitrypsin (AAT) deficiency in a new article in the peer-reviewed journal Human Gene Therapy. In ATT deficiency, neutrophil proteases destroy the lung parenchyma, the portion of the lungs...

Weill Cornell study demonstrates safety of intravenous administration of an AAV8 gene therapy2024-07-13T13:31:10+00:00
14 02, 2023

Join Avance Biosciences™ at the mRNA Analytical Development Summit Feb 14-16, 2023!

2023-02-21T17:19:15+00:00

With several years of experience supporting a world-renowned mRNA COVID-19 vaccine company with raw material and drug substance release, Avance Biosciences™ is well-positioned to provide industry-leading assay design, validation, and sample testing services that advance our clients’ mRNA therapeutic...

Join Avance Biosciences™ at the mRNA Analytical Development Summit Feb 14-16, 2023!2023-02-21T17:19:15+00:00
6 12, 2022

CG Oncology advancing clinical-stage urologic oncology immunotherapy pipeline

2022-12-06T19:23:30+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

CG Oncology advancing clinical-stage urologic oncology immunotherapy pipeline2022-12-06T19:23:30+00:00
30 11, 2022

Join Avance Biosciences™ at the Gene Therapy Analytical Development Summit Nov 28 – Dec 1 2022

2022-11-30T15:03:21+00:00

Avance offers a broad range of assay development services, including assay design, assay validation, sample testing, and technology transfer under GLP compliance to support IND-enabling and clinical studies. With decades of experience helping gene and cell therapy companies, Avance Biosciences™ has the...

Join Avance Biosciences™ at the Gene Therapy Analytical Development Summit Nov 28 – Dec 1 20222022-11-30T15:03:21+00:00
22 11, 2022

Quantification of On/Off-Target Gene Editing

2024-07-10T19:27:53+00:00

Quantitative analysis of gene editing is now an essential step in getting regulatory approval of gene editing-based therapies. But designing and validating assays for on/off-target editing analysis and building an internal team to perform them can be costly and inefficient...

Quantification of On/Off-Target Gene Editing2024-07-10T19:27:53+00:00
9 11, 2022

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy

2024-07-13T13:31:55+00:00

Although immunotherapy has revolutionized the treatment of many blood cancers, the field has encountered challenges developing similar treatments for solid tumors. When it comes to pediatric brain tumors, which are the leading cause of cancer death in children, challenges include...

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy2024-07-13T13:31:55+00:00
1 11, 2022

Remarkable results from CAR-T cell therapy for lupus

2024-07-10T19:28:27+00:00

A recent study has shown remarkable results from compassionate use of CAR-T cell therapy to treat severe lupus in five patients in whom multiple other treatments had previously failed. CAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen. This means they mount an immune response against cells with the chosen antigen...

Remarkable results from CAR-T cell therapy for lupus2024-07-10T19:28:27+00:00
26 10, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

2022-10-26T14:30:28+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis2022-10-26T14:30:28+00:00
18 10, 2022

A report on the state of the cell and gene therapy industry

2022-10-18T15:39:46+00:00

Twice a year, the Alliance for Regenerative Medicine (ARM) surveys the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to their members, their stakeholders, and the public at large. While external conditions ebb and flow, the sector’s progress — in clinical milestones, regulatory developments, and patient impact — steadily advances...

A report on the state of the cell and gene therapy industry2022-10-18T15:39:46+00:00
Go to Top